Drug profile

The FDA adverse-event record for Telmisartan

530 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Telmisartan. See the species affected, top reactions, and outcomes below.

530
adverse-event reports
7.2%
death-coded share
Cat
most-reported species
113
Lack of efficacy - NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
530
Total Reports
38
Deaths Reported
7.2%
Death Rate

Active Ingredients

Telmisartan

Administration Routes

OralUnknownSubcutaneousTopical

Species Affected

Cat 289
Dog 167
Unknown 72
Human 2

Most Affected Breeds

Domestic Shorthair 170
Unknown 74
Cat (other) 25
Cat (unknown) 24
Domestic Longhair 20
Terrier - Yorkshire 16
Retriever - Labrador 16
Retriever - Golden 11
Domestic Mediumhair 10
Terrier (unspecified) 10

Most Reported Reactions

Lack of efficacy - NOS 113
Vomiting 106
Diarrhoea 55
Weight loss 44
Elevated creatinine 44
Decreased appetite 36
Lethargy (see also Central nervous system depression in Neurological) 34
Elevated blood urea nitrogen (BUN) 30
Lethargy (see also Central nervous system depression in 'Neurological') 27
Anaemia NOS 27
Appearance, Abnormal 27
Death by euthanasia 25

Outcome Breakdown

Outcome Unknown
253 (55.2%)
Recovered/Normal
89 (19.4%)
Ongoing
78 (17.0%)
Euthanized
27 (5.9%)
Died
11 (2.4%)

Telmisartan Adverse Event Insights

530 reports name Telmisartan; 38 recorded a death outcome (7.2% of reported events, not a population-level mortality rate). Active ingredient: Telmisartan. Administration routes: Oral, Unknown, Subcutaneous, Topical.

By species: Cat (289 reports), Dog (167 reports), Unknown (72 reports). By breed: Domestic Shorthair (170), Unknown (74), Cat (other) (25).

Leading clinical signs: Lack of efficacy - NOS (113), Vomiting (106), Diarrhoea (55), Weight loss (44). Outcome, 458 coded reports: Outcome Unknown leads at 55.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.